Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Danske Bank and SEB in relation to Raketech’s listing on Nasdaq First North Premier
Mandate

Vinge advises Danske Bank and SEB in relation to Raketech’s listing on Nasdaq First North Premier

June 20, 2018 Capital Markets and Public M&A

Vinge advises Danske Bank A/S, Danmark, Sverige Filial and Skandinaviska Enskilda Banken (publ) who are acting as Joint Global Coordinators and Joint Bookrunners in connection with the listing of Raketech Group Holding plc – a marketing actor whose primary business involves using its online products to influence iGaming market users who are interested in sports and gambling and to guide them towards the best gambling services – on Nasdaq First North Premier. 

A prospectus was published on 18 June 2018 and the first day of trading on Nasdaq First North Premier is 29 June 2018. The total value of the offering amounts to between approx. SEK 530-550 million, assuming that the over-allotment option is exercised in full.
 
Vinge’s team consist mainly of David Andersson, Amanda Knutsson, Rikard Lindahl and Stephanie Stiernstedt.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025